Drug intelligence / Profile preview

ZSP1602

Development stage: Phase 1
Lead developer: Zhongsheng Pharma
Modality: Small Molecules
Administration: Oral

Overview

ZSP1602 is an orally bioavailable small molecule antagonist of Smoothened (SMO), a key component of the Hedgehog (HH) signaling pathway. It was initially developed by Guangdong Zhongsheng Pharmaceutical. The drug is under clinical evaluation for the treatment of advanced solid tumors, including basal cell carcinoma, adenocarcinoma of the esophagogastric junction, small cell lung cancer, neuroendocrine neoplasms, and other advanced solid tumors. Its mechanism involves inhibition of SMO to suppress tumor growth and proliferation driven by aberrant HH pathway activation[1][2]. Phase 1 clinical trials have been conducted to assess its safety, tolerability, pharmacokinetics, and maximum tolerated dose in patients with advanced solid tumors[1].

Other names: ZSP-1602ZSP1602ZSP 1602

Targets

SMO (Smoothened)

Beyond the preview

Go deeper on ZSP1602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZSP1602.

Explore the full profile